The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict PharMerica's revenues will wither -12.7% and EPS will wither -17.1%.
The average estimate for revenue is $432.4 million. On the bottom line, the average EPS estimate is $0.29.
Last quarter, PharMerica chalked up revenue of $442.0 million. GAAP reported sales were 15% lower than the prior-year quarter's $518.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.33. GAAP EPS of $0.20 for Q3 were 25% higher than the prior-year quarter's $0.16 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 17.1%, 250 basis points better than the prior-year quarter. Operating margin was 4.2%, 80 basis points better than the prior-year quarter. Net margin was 1.4%, 50 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $1.83 billion. The average EPS estimate is $1.23.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 121 members out of 126 rating the stock outperform, and five members rating it underperform. Among 22 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 21 give PharMerica a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on PharMerica is outperform, with an average price target of $14.16.
Is PharMerica the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add PharMerica to My Watchlist.